Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Bordeaux, Jennifer M ^a   Cheng, Huan ^a   Welsh, Allison W ^a   Haffty, Bruce G ^a   Lannin, Donald R ^a   Wu, Xingyong ^b   Su, Nan ^b   Ma, Xiao Jun ^b   Luo, Yuling ^b   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Advanced Cell Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN ANTIBODY; TAMOXIFEN; UBIQUITIN C; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA, HUMAN; RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AQUA METHOD; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ESR1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; ONCOGENE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TREATMENT OUTCOME; AGED; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN;

EID: 84860992610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036559     Document Type: Article

References (20)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
2. Dowsett M, Dunbier AK, (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14: 8019-8026.
3. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, et al. (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53: 1084-1091.
4. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, et al. (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28: 1677-1683.
5. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
6. Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F, (2007) Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4: 147-155.
7. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
8. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, et al. (2011) Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. J Clin Oncol 29: 4160-4167.
9. Wang F, Flanagan J, Su N, Wang L, Bui S, et al. (2011) RNAscope: A Novel In Situ RNA Analysis Platform for Formalin-Fixed Paraffin-Embedded Tissues. J Mol Diagn 14: 22-29.
10. Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, et al. (2011) High-Risk Human Papillomavirus E6/E7 mRNA Detection by a Novel In Situ Hybridization Assay Strongly Correlates With p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma. Am J Surg Pathol 35: 1343-1350.
11. Masand RP, El-Mofty SK, Ma XJ, Luo Y, Flanagan JJ, et al. (2011) Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol 5: 108-116.
12. Liu X, Bates R, Yin DM, Shen C, Wang F, et al. (2011) Specific regulation of NRG1 isoform expression by neuronal activity. J Neurosci 31: 8491-8501.
13. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, et al. (2011) Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 3: 98ra82.
14. Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, et al. (2011) Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue-a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 20: 1-10.
15. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, et al. (2011) Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 29: 2978-2984.
16. Lacroix M, Querton G, Hennebert P, Larsimont D, Leclercq G, (2001) Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison. Breast Cancer Res Treat 67: 263-271.
17. Pusztai L, Ayers M, Stec J, Clark E, Hess K, et al. (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9: 2406-2415.
18. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, et al. (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8: 203-211.
19. Welsh A, Lannin D, Young GS, Sherman ME, Figueroa JD, et al. (2011) Cytoplasmic Estrogen Receptor in Breast Cancer. Clin Cancer Res.
20. Camp RL, Chung GG, Rimm DL, (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327.